<SEC-DOCUMENT>0001144204-13-029618.txt : 20130701
<SEC-HEADER>0001144204-13-029618.hdr.sgml : 20130701
<ACCEPTANCE-DATETIME>20130515164938
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-13-029618
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20130515

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAMADA LTD
		CENTRAL INDEX KEY:			0001567529
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
		BUSINESS PHONE:		97289406472

	MAIL ADDRESS:	
		STREET 1:		7 SAPIR ST. WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			74140
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%; padding-top: 0; padding-right: 0; padding-left: 0; font-size: 10pt; text-indent: 0"><IMG SRC="image_001.jpg" ALT="" STYLE="height: 30px; width: 240px"></TD>
    <TD STYLE="width: 28%; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">425 Market Street<BR>
        San Francisco<BR>
        California 94105-2482</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">Telephone: 415.268.7000</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">Facsimile: 415.268.7522</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase">www.mofo.com</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P></TD>
    <TD STYLE="width: 26%; padding-right: 0; padding-left: 0; padding-top: 0; text-indent: 0">
        <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">morrison <FONT STYLE="font-size: 10pt">&amp;</FONT>
        foerster llp</P>
        <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">new york, san francisco,<BR>
        los angeles, palo alto,<BR>
        sacramento, san diego,<BR>
        denver, northern virginia,<BR>
        washington, d.c.</P>
        <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0">tokyo, london, brussels,<BR>
beijing, shanghai, hong kong&nbsp;</P></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 99%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 1%; padding: 0; text-indent: 0">Writer&rsquo;s Direct Contact</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">May 15, 2013</TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0">415.268.6966</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD NOWRAP STYLE="padding: 0; text-indent: 0">AThorpe@mofo.com</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey P. Riedler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Assistant Director</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 1%; padding-right: 0; padding-left: 0; text-indent: 0">Re:&nbsp;&nbsp;</TD>
    <TD STYLE="width: 99%; padding-right: 0; padding-left: 0; text-indent: 0">Kamada Ltd.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Registration Statement on Form F-1</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Filed April 11, 2013</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">File No. 333-187870</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Mr. Riedler:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We enclose herewith, on behalf of Kamada Ltd.
(the &ldquo;Company&rdquo;), clean and marked copies of Amendment No. 1 to the Registration Statement on Form F-1 (&ldquo;Amendment
No. 1&rdquo;), together with responses to the comments raised by the Staff of the Securities and Exchange Commission (the &ldquo;Staff&rdquo;)
in its comment letter dated April 19, 2013. Amendment No. 1 incorporates responses to the Staff&rsquo;s comments. Below, we have
noted the Staff&rsquo;s comments in bold face type and the Company&rsquo;s responses in regular type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Use of Proceeds, page 46</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD><B>We note your response to prior comment 3 and your revised disclosure on pages 9 and 46 of the prospectus. Notwithstanding
your response that the company has not yet made specific determinations regarding the amount of proceeds that will be devoted to
particular uses, and therefore is not able to quantify such amounts at this time, Item 504 of Regulation S-K requires registrants
to approximate the amount of proceeds intended to be used for each intended purpose. As you have listed five specific uses for
the proceeds on pages 9 and 46, you should also provide an estimated breakdown of the proceeds among these items. This is required
even if, as you note in your prospectus, management will have broad discretion in allocating the proceeds and that the expected
uses depend on numerous factors and are subject to change.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="" STYLE="width:
240px; height:
30px"></P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey P. Riedler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 2</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Response</U>: The Company acknowledges the Staff&rsquo;s
comment and has revised the disclosure on pages 9 and 47 to include an estimated range of the net proceeds of the offering that
the Company currently intends to use for its clinical trials. The Company also disclosed that the remaining net proceeds are currently
intended to be used for the other uses listed, thus providing investors with an indication of the approximate amounts for the remaining
uses as a group. The Company is unable to quantify the approximate amount of net proceeds that will be devoted to a particular
clinical trial or any of the particular remaining uses at this time because this information is unavailable since the Company has
not made specific determinations regarding the amounts of such expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Note 19: Contingent Liabilities and Commitments, page
F-32</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD><B>We acknowledge your response to our comment 11 and your revised disclosure. Please address the following additional comments:</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><B>&middot;</B></FONT></TD><TD><B>In your response, you indicated that you revised the disclosure to address our comment to clarify the &ldquo;certain conditions&rdquo;
under which you are obligated to fund this development; however, we did not see revised disclosure. Accordingly, please revise
your disclosure or tell us where you have provided this disclosure in the filing.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol"><B>&middot;</B></FONT></TD><TD><B>Please tell us why you do not anticipate that you will be obligated to fund these clinical trials. We noted your disclosure
on page 79 that you expect that the Phase IV clinical trials will be substantially financed by Baxter, which appears to imply that
you will have to bear some portion of the cost.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Response</U>: The Company acknowledges the Staff&rsquo;s
comment and has revised page F-32 to remove the reference to &ldquo;certain conditions&rdquo; in order to properly reflect the
Company&rsquo;s agreement with Baxter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Company does not anticipate that it will be obligated
to fund Phase IV clinical trials because the Company&rsquo;s agreement with Baxter only obligates the Company to fund a portion
of these clinical trials once the overall costs of the clinical trials have reached a certain amount. The Company does not anticipate
that the costs of the clinical trials will reach this amount, and has assumed as such in its accounting treatment for the Baxter
agreements. The Company has revised page 82 to remove the reference to &ldquo;substantially&rdquo; to make the disclosure consistent
with its accounting treatment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="" STYLE="width: 240px; height: 30px"></P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey P. Riedler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 3</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>Note 22: Share-Based Payment, page F-36</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><B>3.</B></TD><TD><B>We acknowledge your response to our comment 13 and your revised disclosure. Paragraph 16 of IFRS 2 states that &ldquo;an
entity shall measure the fair value of equity instruments granted at the measurement date.&rdquo; In addition, paragraph 19 states
that &ldquo;Vesting conditions, other than market conditions, shall not be taken into account when estimating the fair value of
the shares or share options at the measurement date.&rdquo; Your revised disclosure states that the measurement date has not yet
been met but also indicates that you recognized expense for services received during the vesting period. It appears that this disclosure
is trying to convey how you intend to account for the vesting of these awards upon the measurement date. Please revise accordingly
or tell us why a revision is not necessary.</B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Response</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In response to the Staff&rsquo;s comment, the Company
has clarified the disclosure in Note 22 to indicate that: (i) pursuant to IFRS 2 Para 18-19, the Company <I>will</I> recognize
an expense for services rendered during the vesting period based upon the best available estimate of the number of options expected
to vest, taking into consideration the likelihood of an IPO occurrence; and (ii) as of December 31, 2012, no expense was recorded
since none of the options were expected to vest, as the likelihood of the Company&rsquo;s IPO was not probable at December 31,
2012.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">In addition, the <FONT STYLE="font-size: 10pt">Company
advises the Staff that the vesting conditions were not taken into account when the fair value of the options was measured.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"><IMG SRC="image_003.jpg" ALT="" STYLE="width: 240px; height: 30px"></P>

<P STYLE="margin: 0pt 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey P. Riedler</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">May 15, 2013</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Page 4</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">We appreciate your time and attention to the
Company&rsquo;s responses to the Staff&rsquo;s comments. Should you have any additional questions or concerns, please call me at
415-268-6966.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 50%; padding: 0; text-indent: 0">Sincerely,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">/s/ Andrew D. Thorpe</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-indent: 0">Andrew D. Thorpe, Esq.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Enclosures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 1%; padding-right: 0; padding-left: 0; text-indent: 0">cc:&nbsp;&nbsp;&nbsp;</TD>
    <TD STYLE="width: 99%; padding-right: 0; padding-left: 0; text-indent: 0">Mark Brunhofer (Securities and Exchange Commission)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Daniel Greenspan (Securities and Exchange Commission)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Sasha Parikh (Securities and Exchange Commission)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Amy Reischauer (Securities and Exchange Commission)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">David Tsur (Kamada Ltd.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Gil Efron (Kamada Ltd.)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Bruce A. Mann (Morrison &amp; Foerster LLP)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Michael Kaplan, Esq. (Davis Polk &amp; Wardwell LLP)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Raz Tepper (Fischer Behar Chen Well Orion &amp; Co)</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-right: 0; padding-left: 0; text-indent: 0">Ari Fried (Gornitzky &amp; Co)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X``02D9)1@`!`0```0`!``#_VP!#``@&!@<&!0@'!P<)"0@*#!0-#`L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+#`Q-#0T'R<Y/3@R/"XS-#+_
MVP!#`0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P``1"``>`/`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#W^BO,)/%F
MM^&/'ESIE^]SJFD7;"VT]V1/,6Z$:/Y9**.&W]2.,9[&M3X::IK6LV^M7&M:
MB;F:VU*6S6-(T6)`F/NX&3R3U)X`H`[NBO/=%U36O&,WB2ZAU:33(=/O)+*R
MAAC0X:,<O+N!+9)'R\`#WYK0\*^([SQ=\-TU:1FLKUXI%>2W`P'0D%EW`C!Q
MWSUH`[*BO$='\;>)+_0/#;6>IWESXCU*X.;:XM8TM985=@Y#;!T4#[K9SVKO
M?B?J>I:)X&O-6TJ^DM+JU*%2J(RON<*0P8'C![8H`[&BO.-#\0:O?>/;;3+"
M]O+NP@M2^K)J-ND3P.RYC*856.?H1CO5OQIJ&K6/C+PK9V.K7%M:ZK</!<1(
MD9X5=P*EE)!/0T`=Y17(^/-0\0:?96+:#:37*F?-ZEIL-QY('/EAN,Y(R<''
MXYJCX#\3G7=9U6W.J7LH@BBVZ?J-H(+FV.6W%B``X/RX/M^)`.\HKSW1=4UK
MQC<>)+F'5I-,ATZ[DLK*&&-#AD',DNX$MDD?+P`/?FM3P;KMYXV^']O?R2M8
M7TRO&\UNH.UT8J64,",''0YZXH`ZZBO&8O'6OP:(^E^(+]].U:2W:ZTK5(HX
M_*OACA&!4@/TX&.WX^OV=O):VD<,MU+=.HYFFV[F^NT`?I0!S_Q&_P"2=:]_
MUZ-72I_JU^@KFOB-_P`D[U[_`*]&KI4_U:_04`.HKF/B!>7VF>"M3U/3KZ6T
MNK*%ID9%1@Q'9@P/'TQ65X/O]:U>[L;B2^U(01V<4MW%?6\2I<-*A(:$JH.%
M9>YZ'VY`.\HK@]-U75?%OBOQ)90ZE-IEEH\JVL*VZ(7DE(),CE@>/11C/>KO
M@+Q#>^+/"D\E\PBOK>YFLI9[<`!V0X\Q0<@9R#CD9H`Z^BO'M)\0^)-2@U.U
M.L:L+M-7FT^VO8[2`V\*J/E:;Y/;G&.HKT;Q%)=P^#K^ZMKUH+NWLWG2>$*V
M65"W1@002/3I0!MT5X_H?C#7]1D\)066HW=UJE\J7&HVUW;)'#]F_CD1MJG@
M]-I-=GX\U'Q!I]E8MH5I/<J9\WJ6FTW`A`Y\L-D$Y(R<'&?QH`ZVBN$\!^)_
M[=UC5(#JMY*L$<16PU"T$%S;'+;BV``X/RX/_P"LT-0G\2:?XX\.Z%-XDN73
M4TNI)WC@A79L&Y`F4.`,@'.<XH`]*HKG=5CU6R\"W#2:M(-3L[-I6NX8T'F.
MB$Y*D$8)'(Q7(^$-:U_7;?P_/)J>I122P+=W;W5M"+6X7<%,<;!=P8[@1SV]
M^`#U"HYO]6/]]?\`T(5Q?Q3U?5-`\,0ZEI5_+:S+=Q0L$C1PZNP!R&4\CMC]
M:IZ%KVJZEXZNK"QO+J]T2TB5;UK^!8I8+DN-JJ`JL05YY&/>@#I['PM;6-U<
MW)OKZYEN'\TFYD5]DFT()$^7Y6"C;QV[4GAOPG9>%OM8L;F]D6[E,\JW$N\&
M0_>?IP3WK>HH`YRZ\%Z=/=ZA<6]Q>V)U(8O4M)MBSG&-Q&#M;'!9<$^M:*:'
M96V@#1;%6L;-8O)C%L=K(OL3GGW]ZTJ*`.-3X9:#'H-II"RWXAL9_M%E*+C$
MMJ^<G8V,@$DG!S6OXB\,6?B?1?[)U">[^R';YBQ2[3+C!&XXYY`/UK;HH`YQ
M?!6FKK6GZPL]Z-1LHO(^T";#3QYR$EP,,*=K?A"RUW6+#4[F[OH[BP8O;"&8
M*L;'J<8Y)''-=#10!CZSX;M-;O+"\FGNX+FQ+FWEMIC&5+@`YQUX'0\>H-.T
MSP[9Z9J-UJ0>>YU"Z54ENKA@7*+]U1@``#)X`'O6M10!SEUX+TZ>\U"YM[B]
ML6U)<7J6DVQ9^,;B"#M;'&Y<$^M:<&C6EEHD>D:<'L+6*,1Q?9B`T8'H2#S[
MGUK0HH`YB7P)I%SX;30KQKJ[M(F5H&N)`TD!7[I1L9&/?/ITKIZ**`.8^(W_
M`"3K7O\`KT:NE3_5K]!61XLTF?7?"FIZ7:O&D]U`T:-*2%!/K@$_I6PHPH'H
M*`,OQ#H%OXETF33+RXN8K68%95MW"F1?[I.#Q],5-HVE1Z+ID.GPW%Q/#"H2
M,W#!F50``N0!P`*OT4`8%UX2LI]6N=4M;F\T^\NXA%<R6<H3S@.A8$$;AV88
M/O5W3-!L=%T--(TN-K.V1"J&,Y<$]6R<Y;)SDYYK2HH`XQ/AKID6F7^G1ZIK
M*6M_*\UTBW0!E=_O$G;GGN,XKH=0T6#4="?1VFN(;9XA"S0N%<IC!&<'J.*T
MJ*`.0'PYT9;#2;99[]7TARUC<K/B:%3U0,!RO'0@UKZSX;M-;O+"\FGNX+FP
M+FWEMIC&5+@`Y]>!T/'J#6Q10!DZ9X=L],U&ZU+S)[G4+I526ZN&!<HOW5``
M``&3P`/>JFI>#[/5/$EGKTM[J$=Y9@BW$4H5(P1A@!MYW#KFNAHH`H:QI::U
MIDVGRW%Q!%,I21K=@K,I&"N2#P0:PK7X?Z=:1Z5`NH:H]KI4B2VML]P/+5E^
M[D!1NQ[UUE%`&%XH\*V/BVRBL]0GNTMXY!+LMY`FYARI/!/!Z5!_PB&GV_B&
F'Q!'-=KJ(B2WGD$N!<J"`#*H&&(]1BNDIDBEU`']X'\B#0!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!PD'!@H)"`D+"PH,#QD0#PX.
M#QX6%Q(9)"`F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$!`)C!&2T4^2CD_0#W_
MP``+"``>`/`!`1$`_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+
M_\0`M1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$(
M(T*QP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%56
M5UA96F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBI
MJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W
M^/GZ_]H`"`$!```_`/9J*************H:]_P`B]J7_`%ZR_P#H!J/PU_R*
M^D_]></_`*`*TZ*************X'_A+]1T#QC<Z9K#O>6$H\NRF6)5=IPJM
MY9V\9.\`?A[UH>`M7U;6DU6;5[B-GM[V2U6&*,!$VXZ'J>N.?2F:;JVK^*;S
M6VT^\2PM["=K2W7R5<R2*.6?=_#G'`P<=ZN^&?$$_BKP:M^I^QW9#QN44,$D
M4X)4'J.,\^M<7I_CK6[K0-.N+>_%WK=U<%%T[[(`DJ!B&(8`8PO).>*[7QWJ
M-]H_A"\U+3;@07%JH<`H'#\@8.?K^E8ND^)]2N_$NEV5E>G4XI82^HJ]L(C:
M94%2&`'4Y`!SFKWC35-4TW5M"BTZ^\B+4+M;653"K[0>=P)[_I5[QCJ>J:1H
ML4^E6TURWG(MPT,8DDCB_B=4Z$\?3FL[PAXG_M[6;F*'5A=6\<`/V>>W\FYB
M?=SN&`&&.X_^O4EEJ^I^)/$6MVEE>#3[72W%NK+$KO+*1DLV[@*,=!@GUJSX
M1UZZ\4^&II9BMK?0S26LKQ+E1(O&Y0<\<@X-<W;>,]6@6YTK6[E+2];S6T_4
M5A7RKG86!0J>`V5Z?UQGN=#%T='MGOKHW,\D:R,^P(`2`<`#M2Z]_P`B]J7_
M`%ZR_P#H!J/PU_R*^D_]></_`*`*DULW":-=2V=P;>:*-I%<('Z`G&#7&^$?
M$6L^((M)<Z@YN)8_M-U%)9A(FB#[2$?&2W(/&1UZ5KSZU?:GXYFT"PG%G!96
MRSW$X0/([-]U5W9`&#DG!].*E\)Z_=ZG=:OIFH^6UWI5QY+3QKM652,JV.QP
M.1TKG)/$^JVFNZ[8W>K7/E6!A6&2"P60DR#^/C``)'<=Z[FRAU`Z+%%?7*#4
M/*VR3PJ-N_\`O`$8_"O-K3QUK4WAY9X]1%QK;W;0V]@+,;;@*X!Y`XXR2<\5
MWOBC4-5T[PQ/=:39_:+]57$2C?MR1N('\1`R<=\5@^&?%IUGQ%%:0ZLTD8B<
MS6=[:B"Y5AC!&`%8=>!R/?L[QAJ.O:$T-S#J4:PW>I0VL4(@5MD3#DDGDMD'
MVKI;&UU-+"XAOK]9)S(WDW$<2J50_=RN,9'Y5PFD^)]=U2SFB&JR)J+7\MG;
MG[`#`=@)&]L<9P>ASTXKMO$MQ=V?AB^NK.X$%S;P-,K;`X)52<$'L<5QVE>,
M-6O)_#T=I>C4+N]"/?VAM=@@B(^:0,`,`'@=0:ZJU\,F.\FN;R_>]=Y?M$?F
MPH!#+L"!UP/[HQBE\->&/^$;-X$OY[E+N9KAUE1!B1OO$8`Z^E1R>$Q%>ZA<
M:5J-QIXU$[KI(U5@6Q@NN1\K$=3T]JO66AV^DZ`FE:4S6L4:%$<`.P)ZL<\$
MDY/-<_%\-[6'0K73DU*\#6,_VBSN5""2!B23@@8()/0UM^(/#_\`PD6@/I5Q
M>S11RJ%FD15W2`?48&2,\523P:D6J:=J46HW,=]9Q"WDE54`N8AT5UQCCU%3
M>(?"_P#;]]I]RVH3VQL)1/"L:(1Y@_B.0<_2K6L:&VK26,JW]S:36<AD22#:
M"Q*E<$$$$<]*CL/#J6VMRZQ=W#76H/"+<2;%15C!S@*.Y/4DGMTJ*;PN(]6N
M]1TJ^FT^>^4+<A$5UD(&`X!'#`=_S!JUI.@VVA:(--TMGA4!B)6P[ESR7;/4
MDUF3^"+;4/#]QI&JW4M[#(S21R.B*\+L2Q92H'.6/\NE=%;0_9[6*'=N\M`F
M<8S@8S577O\`D7M2_P"O67_T`U'X:_Y%?2?^O.'_`-`%3ZI92:CITUK%<M;&
M52C2*@8[3P1@\53\,^'_`/A&M)CTY+R2YMX1MA\Q%#(,DD9'7DTV_P##:3ZV
MFL6-S)9:@(O(>15#++'G.&4]<'H>#4NA>'[;08;CR9))KB[E,]S<2D%Y7/<X
MP`/0#@5EV_@VZM=1U*^@UVY2YU$*)W$$?&T87:,<<&M?3=);2M`ATVWNY6:&
M/8MQ(`SD_P!X]B>:YV'X;6L>@_V8VI7;>7<_:[:X`59+>7))(('(.>AK>U70
MVU?3+:UFU"ZBE@E27[3!M21F7OTP,_3%0P>&@=<M]6U&[>\N[6-HX#Y:QA`W
MWB<=3C\!S@4WQ/X8/B9+1'OYK:.VF6X58D4YD7[I)(/3/2M=XIFLC$MP5GV;
M?.V`_-C[V.GX5RL'@&6UT>\TRWU^]BM[R5Y9BL48=F?[V&QP#[5T&K:4=3T2
M;35N7MTFC\IY$4,VTC!'/'([UAQ^`HH8M(:'4[J.\TD>7!<HJ!C%T\MAC#"N
MMHHHHHHHHHHHHHJAKW_(O:E_UZR_^@&H_#7_`"*^D_\`7G#_`.@"M.BBBBBB
(BBBBBBBO_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
